Key Highlights
- Morgan Stanley increased its Alnylam price target to $400 from $370 while maintaining an Equal Weight rating.
- H.C. Wainwright adjusted its price target on Alnylam to $485 from $470, reflecting long-term growth projections.
- Analysts noted improved market dynamics for Alnylam’s rare disease therapies amid a shifting competitive environment.
Wall Street analysts are recalibrating expectations for Alnylam Pharmaceuticals as the RNA interference therapeutics sector undergoes significant shifts. These adjustments reflect broader changes in the biotech environment, particularly for companies developing treatments for rare and progressive diseases like transthyretin amyloidosis (ATTR).
What Happened
Morgan Stanley raised its price target on Alnylam to $400 from $370 while maintaining its Equal Weight rating. Raymond James attributed its revision to a competitor’s recent clinical trial failure, which analysts believe has eased competitive pressures in the ATTR treatment space. The firm also highlighted stronger market dynamics for Alnylam’s therapies.
H.C. The firm maintained its Buy rating and projected long-term growth potential for Alnylam’s rare disease portfolio, including adjustments to its outlook for one of the company’s key drugs.
Market Impact
The revised price targets signal growing confidence in Alnylam’s position within the RNA therapeutics sector. The reduction in competitive pressure has strengthened expectations for Alnylam’s pipeline, which includes treatments for hereditary and wild-type ATTR. Analysts’ focus on market dynamics suggests potential improvements in the company’s commercial outlook, a key consideration for biotech firms managing reimbursement and access challenges.
These adjustments also reflect broader trends in the sector, with RNA interference therapies gaining recognition as a promising therapeutic approach. Alnylam’s established leadership in this space positions it to benefit from investor interest in rare disease treatments, particularly those addressing conditions with limited existing options. The long-term projections underscore the confidence analysts have in the company’s ability to expand its market presence.
What's Next
Investors will closely watch Alnylam’s next-generation clinical trial, particularly its performance in patients already receiving standard-of-care therapy. The results could influence near-term sentiment and validate the company’s ability to broaden its addressable market. Additionally, further updates on the commercial performance of its key therapies may provide clarity on their growth trajectory following recent analyst revisions.
The RNA therapeutics sector remains fluid, with competition and regulatory developments likely to shape future valuations. Alnylam’s ability to leverage its market advantages and pipeline strength will be critical in maintaining investor confidence as the sector evolves.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...